Related Experiment Videos
Metabolic changes in the psoriatic lesion during therapy
The British Journal of Dermatology
|April 1, 1984
Summary
Psoriatic plaque treatment with clobetasol propionate normalized epidermal enzymes in 14 days, but not capillary alkaline phosphatase. PUVA therapy normalized all three marker enzymes over 4-8 weeks.
Area of Science:
- Dermatology and biochemistry
- Enzymology in skin disease
Background:
- Psoriatic plaques exhibit altered enzymatic activity.
- Marker enzymes can indicate therapeutic response in skin conditions.
Purpose of the Study:
- To compare the effects of clobetasol propionate and PUVA therapy on marker enzymes in psoriatic plaques.
- To assess the normalization tempo of epidermal and capillary enzymes during treatment.
Main Methods:
- Measurement of three marker enzymes: acid phosphatase, glucose-6-phosphate dehydrogenase, and capillary alkaline phosphatase.
- Enzyme levels were monitored during treatment of psoriatic plaques with clobetasol propionate and PUVA therapy.
Main Results:
- Clobetasol propionate normalized epidermal enzymes (acid phosphatase, glucose-6-phosphate dehydrogenase) within 14 days.
- Capillary alkaline phosphatase levels remained unchanged with clobetasol propionate treatment.
- PUVA therapy led to the normalization of all three marker enzymes over 4-8 weeks.
Conclusions:
- Clobetasol propionate primarily affects epidermal enzymatic activity in psoriatic plaques.
- PUVA therapy demonstrates a broader normalization effect on enzymatic markers, including capillary enzymes.
- Enzyme marker kinetics can differentiate the biological impact of different psoriasis treatments.